.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Medtronic India recently introduced the groundbreaking PulseSelect system to the Indian healthcare market. This innovative technology brings Pulsed Field Ablation to local electrophysiologists for treating atrial fibrillation (AFib). Consequently, patients suffering from irregular heartbeats can now access a safer treatment pathway. Specifically, this next-generation device targets pulmonary veins with high precision, which significantly lowers stroke risks.
Atrial fibrillation currently affects over seven million people in India, creating a massive public health burden. Furthermore, many cases remain underdiagnosed because mild or intermittent symptoms often go unnoticed. If clinicians leave AFib untreated, patients face severe risks of stroke and heart failure. Therefore, continuing medical innovation is essential to strengthen the overall cardiac care ecosystem.
Traditional therapies like radiofrequency ablation and cryoablation rely on extreme heat or extreme cold. However, these thermal energies carry an inherent risk of damaging surrounding healthy tissues. In contrast, Pulsed Field Ablation utilizes short, high-voltage electrical pulses to isolate the pulmonary veins. Additionally, this non-thermal mechanism selectively targets cardiac cells while sparing critical structures like the esophagus and phrenic nerve. Consequently, the procedure offers an exceptional safety profile and supports a smoother recovery.
Electrophysiologists across India have welcomed this technological advancement. For example, prominent hospitals like Kauvery Hospital in Chennai have already launched specialized programs to integrate these advanced platforms. Moreover, clinical data from global trials confirms that the system maintains a high rate of procedural efficiency. As a result, physicians can perform these procedures faster while optimizing laboratory workflows. Ultimately, this launch provides Indian clinicians with a powerful tool to enhance precision and improve long-term patient outcomes.
Q1: What is Pulsed Field Ablation and how does it work?
Pulsed Field Ablation is a next-generation cardiac treatment. Indeed, it uses short electrical pulses instead of extreme thermal energy to isolate abnormal tissues. Specifically, this non-thermal process targets problematic cardiac cells through electroporation. Consequently, this selective approach avoids damaging nearby critical structures.
Q2: Why is the launch of the PulseSelect system in India significant?
Atrial fibrillation affects millions of people in India, which substantially increases stroke risks. However, the condition remains heavily underdiagnosed across the country. Therefore, introducing this advanced technology provides local physicians with safer and more precise tools.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Medtronic has introduced its innovative PulseSelect Pulsed Field Ablation (PFA) system in India. This next-generation, non-thermal cardiac ablation technology targets atrial fibrillation, reducing tissue damage risks and offering a safer, faster treatment option to help prevent strokes across the country.
2 months ago
A comparative analysis shows that older age, elevated blood glucose, and abdominal adiposity are primary drivers of hypertension. Comprehensive evaluation of cardiometabolic risk profiles enables clinicians to detect overlapping metabolic dysfunctions early and optimize targeted prevention strategies.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Left ventricular thrombus is a severe complication of acute decompensated heart failure. This clinical review explores the pathophysiology, imaging challenges, and pharmacotherapeutic considerations of laminated thrombi, evaluating the evolving role of direct oral anticoagulants versus traditional warfarin.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
